Mergers & Acquisitions ·
NextCure announced its second quarter 2026 financial results and provided a business update regarding its proposed…
NXTCNextCure, Inc.
NextCure announced its second quarter 2026 financial results and provided a business update regarding its proposed all-stock merger with Avere Therapeutics. The transaction, expected to close in the second half of 2026, will result in the combined entity operating as Avere Therapeutics under ticker AVRX on Nasdaq. Existing NextCure shareholders are expected to receive contingent value rights tied to legacy assets. Concurrently, Avere secured a private financing expected to generate approximately $320 million in gross proceeds. For the quarter ended June 30, 2026, NextCure reported cash and marketable securities of $20.1 million, R&D expenses of $7.4 million, and a net loss of $14.9 million. The company also announced restructuring initiatives including asset impairments totaling $5.1 million and a transition agreement with LigaChem Biosciences for the LNCB74 program. NextCure is a clinical-stage biopharmaceutical company focused on discovering and developing novel cancer therapies.